XOMAP
XOMA Corporation [XOMAP] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
XOMAP Stock Summary
In the News
XOMAP Financial details
Company Rating
-
Market Cap
299.97M
Income
-48.74M
Revenue
4.76M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
13
Optionable
No
Shortable
Yes
Earnings
31 Mar 2023
P/E
-6.97
Forward P/E
-
PEG
-0.38
P/S
54.74
P/B
2.28
P/C
-
P/FCF
-13.33
Quick Ratio
3.26
Current Ratio
3.34
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-4.25
EPS next Y
-
EPS next Q
-
EPS this Y
137.33%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
32.25%
Revenue last 5Y
-23.68%
Revenue Q/Q
120.84%
EPS Q/Q
264.58%
-
-
-
-
SMA20
0.86%
SMA50
0.58%
SMA100
0.08%
Inst Own
-
Inst Trans
-
ROA
-28%
ROE
-30%
ROC
-0.25%
Gross Margin
83%
Oper. Margin
-638%
Profit Margin
-785%
Payout
-16%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
21.4-25.98
52W High
+3.4%
52W Low
+23.1%
RSI
51.39
Rel Volume
0.84
Avg Volume
1.4K
Volume
1.18K
Perf Week
-1.52%
Perf Month
0.7%
Perf Quarter
-1.71%
Perf Half Y
-1.49%
-
-
-
-
Beta
0.589
-
-
Volatility
0.2%, 0.24%
Prev Close
-0.39%
Price
25.85
Change
-0.39%
Company Profile
- Volume Average 1.4K
- Market Capitalization 299.97M
- Employee 13
- CEO Mr. Owen P. Hughes Jr.
- Headquarters EmeryVille,CA,US
- IPO Date 2020-12-16
-
Website
https://www.xoma.com 
XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
